S
Sonoma Pharmaceuticals, Inc.
SNOACIK 0001367083NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Mar 31
Period
FY 2025
Revenue
$14.29M
Net Income
$-3.46M
Total Assets
$13.69M
Equity
$4.41M
Shares Out
1.73M
Op. Cash Flow
$-88.0K
Business
Sonoma Pharmaceuticals, Inc. develops and manufactures stabilized hypochlorous acid (HOCl) healthcare products for therapeutic and consumer use. It offers wound care, dermatology, eye, oral, nasal, podiatry, animal health and surface disinfectant products in prescription, over-the-counter and office-dispense formats. Its business is organized across key channels including dermatology, first aid and wound care, eye care, oral/nasal care, podiatry, animal health and surface disinfectants, supported by manufacturing and R&D operations. Products are sold directly and via partner distributors across the United States, Europe, Asia, Canada, the Middle East and other international markets.
Summary from filing dated 2025-06-17
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 | FY 2021 2021-03-31 |
|---|---|---|---|---|---|---|
| Revenues | 14 | 13 | 13 | 13 | 19 | |
| Cost of revenues | 9 | 8 | 9 | 9 | 12 | |
| Gross profit | 5 | 5 | 4 | 4 | 7 | |
| Research and development | 2 | 2 | 207,000 | 125,000 | 555,000 | |
| Selling, general and administrative | 7 | 8 | 9 | 10 | 9 | |
| Total operating expenses | 9 | 9 | 9 | 10 | 10 | |
| Loss from operations | −4 | −5 | −5 | −6 | −3 | |
| Other income (expense), net | 803,000 | −330,000 | −614,000 | −394,000 | −594,000 | |
| Loss from operations before income taxes | −3 | −5 | −5 | −5 | −4 | |
| Income tax (expense) benefit | −550,000 | 196,000 | 33,000 | 332,000 | −713,000 | |
| Net loss | −3 | −5 | −5 | −5 | −4 | |
| Net loss per share: basic | −2.79 | −10.63 | −1.52 | −1.92 | — | |
| Net loss per share: diluted | −2.79 | −10.63 | −1.52 | −1.92 | — | |
| Weighted-average number of shares: basic | 1 | 455,000 | 3,394 | 2,653 | — | |
| Weighted-average number of shares: diluted | 1 | 455,000 | 3,394 | 2,653 | — | |
| Foreign currency translation adjustments | −2 | 695,000 | 894,000 | 267,000 | 1 | |
| Comprehensive loss | −5 | −4 | −4 | −5 | −3 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 | FY 2021 2021-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 3 | 4 | 7 | 4 | |
| Accounts receivable, net | 2 | 3 | 3 | 2 | 3 | |
| Inventories, net | 3 | 3 | 3 | 3 | 3 | |
| Prepaid expenses and other current assets | 2 | 4 | 4 | 4 | 3 | |
| Current portion of deferred consideration, net of discount | 212,000 | 262,000 | — | — | — | |
| Total current assets | 13 | 13 | 14 | 16 | 13 | |
| Property and equipment, net | 225,000 | 365,000 | 488,000 | 320,000 | 360,000 | |
| Operating lease, right of use assets | 84,000 | 286,000 | 418,000 | 559,000 | 769,000 | |
| Deferred tax asset, net | 589,000 | 1 | 949,000 | 829,000 | 0 | |
| Deferred consideration, net of discount, less current portion | 73,000 | 330,000 | — | — | — | |
| Other assets | 74,000 | 66,000 | 73,000 | 77,000 | 112,000 | |
| Total assets | 14 | 15 | 16 | 19 | 15 | |
| Accounts payable | 953,000 | 607,000 | 841,000 | 2 | 2 | |
| Accrued expenses and other current liabilities | 2 | 2 | 2 | 2 | 1 | |
| Deferred revenue, current portion | 641,000 | 478,000 | 160,000 | 1 | 267,000 | |
| Short-term debt | 220,000 | 323,000 | 431,000 | — | — | |
| Operating lease liabilities, current portion | 58,000 | 198,000 | 256,000 | 250,000 | 240,000 | |
| Total current liabilities | 4 | 4 | 4 | 6 | 4 | |
| Deferred revenue, net of current portion | 17,000 | 87,000 | 140,000 | 182,000 | 229,000 | |
| Withholding tax payable | 5 | 5 | 4 | 4 | 3 | |
| Operating lease liabilities, less current portion | 27,000 | 87,000 | 162,000 | 309,000 | 529,000 | |
| Total liabilities | 9 | 9 | 8 | 10 | 10 | |
| Commitments and Contingencies (Note 11) | — | — | — | — | — | |
| Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2025 and 2024, respectively, no shares issued and outstanding at March 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at March 31, 2025 and 2024, respectively, 1,634,265 and 780,371 shares issued and outstanding at March 31, 2025 and 2024, respectively (Note 1) (Note 12) | 0 | 0 | 5,000 | 2,000 | 2,000 | |
| Additional paid-in capital | 207 | 203 | 201 | 197 | 189 | |
| Accumulated deficit | −198 | −194 | −190 | −184 | −179 | |
| Accumulated other comprehensive loss | −4 | −3 | −3 | −4 | −5 | |
| Total stockholders equity | 4 | 6 | 8 | 9 | 5 | |
| Total liabilities and stockholders equity | 14 | 15 | 16 | 19 | 15 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 | FY 2021 2021-03-31 |
|---|---|---|---|---|---|---|
| Depreciation | 138,000 | 176,000 | — | — | — | |
| Stock-based compensation | 224,000 | 516,000 | 669,000 | 382,000 | 371,000 | |
| Deferred income tax expense | 357,000 | −109,000 | −37,000 | −829,000 | — | |
| Operating lease right-of-use asset | 174,000 | 161,000 | 173,000 | 223,000 | 0 | |
| Accounts receivable, net | 434,000 | −230,000 | −4,000 | 2 | 3 | |
| Inventories, net | −388,000 | 184,000 | 0 | −100,000 | −65,000 | |
| Prepaid expenses and other current assets | 1 | 1 | −306,000 | −460,000 | −5,000 | |
| Deferred consideration, net of discount | 194,000 | 222,000 | — | — | — | |
| Accounts payable | 416,000 | −278,000 | −864,000 | −157,000 | −796,000 | |
| Accrued expenses and other current liabilities | 295,000 | 19,000 | 127,000 | 679,000 | −668,000 | |
| Withholding tax payable | 432,000 | 475,000 | 396,000 | 360,000 | 397,000 | |
| Operating lease liabilities | −174,000 | −161,000 | −173,000 | −222,000 | −215,000 | |
| Deferred revenue | 181,000 | 355,000 | −1 | 900,000 | −15,000 | |
| Net cash used in operating activities | −88,000 | −2 | −6 | −4 | −3 | |
| Purchases of property and equipment | −80,000 | −2,000 | −269,000 | −137,000 | −179,000 | |
| Net cash used in investing activities | −80,000 | −2,000 | −258,000 | −99,000 | 388,000 | |
| Proceeds from issuance of common stock, net of offering expenses | 3 | 2 | 3 | 8 | 0 | |
| Proceeds from exercise of employee stock options | 82,000 | 0 | 0 | 216,000 | 2 | |
| Payments for fractional shares related to reverse-split | −1,000 | 0 | — | — | — | |
| Principal payments on short-term debt | −404,000 | −481,000 | −774,000 | — | — | |
| Insurance premiums financed | 274,000 | 373,000 | — | — | — | |
| Net cash provided by financing activities | 3 | 2 | 2 | 7 | 3 | |
| Effect of exchange rate on cash and cash equivalents | −616,000 | 32,000 | 345,000 | 127,000 | — | |
| Net increase (decrease) in cash and cash equivalents | 2 | −692,000 | −4 | 3 | 529,000 | |
| Cash paid for interest | 11,000 | 22,000 | 17,000 | 24,000 | 12,000 | |
| Insurance premiums financed | 274,000 | 373,000 | 515,000 | 748,000 | 596,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro